Inhibikase Therapeutics Inc. (NASDAQ: IKT) announced the enrollment of the first patient in its global phase 3 study IMPROVE-PAH, evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE